AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Sep 2022: Trial registered, NCT05538624
  2. 9 Dec 2022: Trial started, NCT05538624
  3. 10 Apr 2024: Trial terminated, NCT05538624

The trials

NCT05538624: A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

State
Stopped early
Phase
Phase 1 and Phase 2
People
14 taking part
Started
9 Dec 2022
Primary completion
1 Apr 2024
Arms
Part 1 escalating AVB-001 between 0.6 and 3.6 ug hIL-2/kg/day; and Part 2 AVB-001 at the MTD/RP2D
Results
None posted
  1. 14 Sep 2022: Trial registered
  2. 9 Dec 2022: Trial started
  3. 10 Apr 2024: Trial terminated

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.